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Abstract
Purpose: To implement and characterize a fluorine-19 (19F) magnetic resonance imaging (MRI) technique and to test the
hypothesis that the 19F MRI signal in steady state after intravenous injection of a perfluoro-15-crown-5 ether (PCE) emulsion
may be exploited for angiography in a pre-clinical in vivo animal study.
Materials and Methods: In vitro at 9.4T, the detection limit of the PCE emulsion at a scan time of 10 min/slice was
determined, after which the T1 and T2 of PCE in venous blood were measured. Permission from the local animal use
committee was obtained for all animal experiments. 12 ml/g of PCE emulsion was intravenously injected in 11 mice. Gradient
echo 1H and 19F images were obtained at identical anatomical levels. Signal-to-noise (SNR) and contrast-to-noise (CNR)
ratios were determined for 33 vessels in both the 19F and 1H images, which was followed by vessel tracking to determine
the vessel conspicuity for both modalities.
Results: In vitro, the detection limit was ,400 mM, while the 19F T1 and T2 were 1350640 and 2562 ms. The 19F MR
angiograms selectively visualized the vasculature (and the liver parenchyma over time) while precisely coregistering with
the 1H images. Due to the lower SNR of 19F compared to 1H (1768 vs. 83649, p,0.001), the 19F CNR was also lower at 1568
vs. 52635 (p,0.001). Vessel tracking demonstrated a significantly higher vessel sharpness in the 19F images (66611 vs.
56612, p = 0.002).
Conclusion: 19F magnetic resonance angiography of intravenously administered perfluorocarbon emulsions is feasible for a
selective and exclusive visualization of the vasculature in vivo.
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Introduction
A considerable research effort is directed at improving the
detection of vascular disease with different modalities such as X-
ray, intravascular ultrasound (IVUS), computed tomography (CT)
and magnetic resonance angiography (MRA) [1]. Because of its
non-invasive nature and lack of harmful radiation, MRA is
considered the most patient-friendly among these techniques,
while soft-tissue characteristics and blood flow can easily be
exploited for contrast generation.
The main challenge for MRA is associated with the fact that
signal originates from water protons, which are abundant in the
entire body. Inevitably, this leads to background signal in the
image and the blood-pool cannot be seen exclusively. This means
that some strategy is needed to attenuate the signal from static
tissue in close proximity to the blood vessels. Contemporary MRA
is therefore commonly performed using intravascular [2] or
extracellular [3] T1-lowering gadolinium (Gd) contrast agents,
time-of-flight (TOF) imaging, or phase contrast (PC) imaging.
Instead of lowering the T1 relaxation time or using flow
characteristics, the frequency of the magnetic resonance imaging
(MRI) signal itself can also be shifted and exploited for contrast
generation. This should be feasible, since in addition to 1H,
magnetic resonance imaging can also detect several other nuclei.
Fluorine (19F) is such a nucleus and when imaged has 85% of the
MRI sensitivity of 1H, as well as MRI-negligible natural
concentrations in the body [4]. When incorporated in perfluor-
ocarbons (PFC, carbohydrates in which all hydrogen has been
replaced by fluorine) the results are biochemically inert, non-toxic
molecules of which some can be used as blood volume expanders
and oxygen carriers, and have been safely and successfully used in
several phase 3 trials in human patients [5]. Since PFCs are both
hydrophobic and lipophobic, they are usually incorporated in
emulsions to allow for a longer circulation time in blood. Such
PFC emulsions have already been used for angiography in
perfused excised organs such as the heart and kidneys [6,7], as
well as in ‘first-pass’ regional angiography of carotid arteries in
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rabbits in combination with a gadolinium contrast agent for fast
imaging [7].
These non-toxic emulsions can thus be directly injected
intravenously and 19F MRI of the blood vessels might also be
performed once they have spread through the entire vasculature.
In a manner similar to off-resonance angiography with iron-oxide
nanoparticles [8], the 19F signal will only originate from the
injected PFC that will remain in the vascular system; no
background signal is expected, and direct flow-independent
imaging of the blood vessels may be feasible. Furthermore, if no
T1-lowering gadolinium is added to the injection, the relaxation
times T1 and T2 of the
19F agent remain constant, and no
adaptations of the pulse sequence parameters as a function of time
after injection will be necessary, and anatomy distant from the
injection site (such as the heart chambers and great vessels) can
also be visualized. Therefore, in this this pre-clinical study in
rodents we wanted to develop, characterize and test a novel 19F
MRI technique in vitro to test the hypothesis in vivo that the 19F MR
signal after systemic perfluorocarbon injection may be exploited
for angiography with conventional non-contrast 1H MRA as a
reference.
Methods
All experiments were performed on a Varian (Palo Alto, CA,
USA) 9.4T animal spectrometer. A dedicated custom-built
quadrature surface coil with 18-mm diameter loops was used for
19F and 1H RF transmission and reception. Preparation of a 10%
perfluoro-15-crown-5 ether (crown ether or PCE) emulsion was
carried out as previously described [9].
To determine its T1 and T2 in an oxygenated and deoxygenated
environment, 0.5 ml of the emulsion was added to 1.4 ml venous
blood as well as to 1.4 ml of saline (to simulate oxygenated blood)
for a final PCE concentration of 50 mM. An adiabatic inversion-
recovery spectroscopy sequence with a repetition time (TR) of 10 s
and an inversion time (TI) that increased from 0.001 to 20 s was
used for T1 determination, while an adiabatic Carr-Purcell-
Meiboom-Gill (CPMG) spectroscopy sequence was applied for T2
measurements with TR=10 s and echo times (TE) ranging from
0.004 to 2 s.
Next, a dilution series helped ascertain the detection limit of the
MRI pulse sequence within a 10 min measurement time limit.
50 mM PCE in the saline sample described above was diluted to a
series with PCE concentrations of 10, 2.0, 0.80 and 0.40 mM.
Subsequently, 19F gradient echo (GRE) images (30630 mm2 field
of view, 64664 resolution, TR/TE=5.4/2.5 ms, slice thick-
ness = 3 mm, 1750 averages, 10 min/slice, 2 slices) were acquired
and the signal-to-noise ratio (SNR) of the unprocessed images was
determined. These in vitro images were then postprocessed and
thresholded at 90% of the maximum signal intensity to improve
detection of weaker signals; the detection limit with the
postprocessing was experimentally determined as SNR=2 in the
original images [10].
For the in vivo part of these studies, which was approved by the
state animal use committee (‘Service de la Consommation et des
Affaires Ve´te´rinaires du canton de Vaud’ authorization number
2374), male balb/c mice (11 animals, 2862 g bodyweight) were
anesthetized with isoflurane and a catheter was inserted into their
tail vein. ECG leads were attached to their paws and the animal
was placed in a dedicated holder on top of the surface coil,
centered between the heart and kidneys. Next, 12 ml/g body-
weight of the PCE emulsion was infused through the catheter over
,3 min.
Non-triggered 1H 1286128 TOF-GRE (TR/TE=6.1/2.8 ms)
and 64664 TOF-GRE (TR/TE=4.7/2.0 ms) images with a high
radiofrequency excititation angle (not quantifiable since it varies
with distance from the surface coil) were acquired in the 3
principal directions (field of view 30630 cm2, slice thickness 2 or
3 mm, 32 averages, 25 s/slice and 10 s/slice, respectively) as well
as 64664 ECG-triggered axial TOF-GRE images through the
heart at the same location (4 averages,,1 min/slice). The coil was
then tuned to 19F, after which the PCE 19F resonance frequency
was determined with a pulse-acquire [11] sequence (1 shot). 19F
GRE imaging at the same exact anatomical level was then
repeated (64664 resolution, TR/TE=4.3/1.8 ms, 1024 averages,
4.7 min/slice).
The SNR and contrast-to-noise ratio (CNR) of a total of 33
vessels (i.e. 3 per animal) were determined in both the 1H and 19F
images. The CNR was defined as (SL2SS)/N, where SL is the
intensity of an ROI in the lumen, SS the intensity of an ROI
immediately adjacent to the vessel and N the standard deviation in
the background. The ‘‘pure’’ contrast, defined as SL/SS, was also
determined for all vessels. The 33 vessels were then tracked with
Soap-Bubble to determine vessel sharpness [12] (conspicuity) on
both 1H and 19F images.
Two-sided, unpaired, non-equal-variance student’s t-tests were
used for statistical comparison of the quantitative findings between
19F and 1H MRA.
In vivo 19F images were post-processed for visualization with a 3-
pixel-diameter Gaussian filter, fourfold cubic interpolation and
thresholding at 20% of the maximum signal, while a maximum
intensity projection (MIP) was generated from all multi-slice
datasets.
Results
The in vitro 19F PCE T1 relaxation time was very similar in saline
and blood (1400630 and 1350640 ms (Fig. 1a)), while the T2 was
significantly reduced in venous blood from 440625 to 2562 ms
(Fig. 1b). In the dilution series, the SNR ranged from ,86 to ,2
and the PCE detection limit within 10 min of scanning time was
400 mM PCE (Fig. 1c–i).
In the in vivo spectra, the PCE’s single resonance was visible with
high SNR (Fig. 2). The resonances of the isoflurane anesthetic,
which is known to build up in the subcutaneous fat [13], were
substantially smaller.
The in vivo 19F MRA protocol was successfully completed in all
11 animals and exclusively visualized the blood-pool and liver at
different anatomical levels (Fig. 3, middle column) while con-
sistently coregistering with the corresponding anatomy on the 1H
TOF images (Fig. 3, left column). The PCE appeared to be well-
distributed throughout the vasculature immediately after injection
and 19F imaging was successful until 5 hours after injection. In the
axial 19F images at the level of the heart, both ventricles were
visible and coregistered with their ECG-triggered anatomical 1H
counterpart (Fig. 3a–c). Similar results were found on coronal
slices where the iliac and renal arteries were visible within the
sensitive volume of the coil (Fig. 3d–f). Slices at the level of the liver
showed the celiac trunk with its three branches, while a signal
increase in the liver was observed over time (Fig. 3h).
In the MIPs, long contiguous segments of thoracic and
abdominal vasculature could be discerned with minimal back-
ground contamination (Fig. 4). Consistent with the spectra, no
signal from isoflurane was observed in regions of subcutaneous fat.
The average SNR of the vessels was 1768 and 83649
(p,0.001) for the 19F and 1H images respectively, while the
CNR was 1568 and 52635 (p,0.001). The ‘‘pure’’ contrast was
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Figure 1. In vitro characterization of the PCE emulsion. a) 19F inversion recovery curve fits to determine T1 in saline (&,T1 = 1400630 ms) and
venous blood (m,T1 = 1350640 ms). b)
19F spin-echo decay curve fits to determine T2 in saline and venous blood, resulting in T2 = 440625 ms in
saline and T2 = 2562 ms in venous blood. (c–i) Images of dilution series in two Eppendorf tubes, one with pure saline, the other with a decreasing
concentration of PCE. c) A 1H reference image, d) Unprocessed 19F MR image with signal only from the tube with 50 mM PCE; the other tube contains
no 19F and therefore generates no signal. e–h) 19F images of different dilutions of the PCE. i) Postprocessed 19F image at the detection limit of
400 mM.
doi:10.1371/journal.pone.0042236.g001
Figure 2. Representative unlocalized in vivo spectrum (single acquisition) acquired in the mouse. The crown ether singlet in the center is
several times higher than and well-separated from the isoflurane resonances to the left.
doi:10.1371/journal.pone.0042236.g002
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1768 and 361 for 19F and 1H, respectively (p,0.001). With
tracking, an average vessel sharpness of 66611 and
56612(p = 0.002) was measured in the 19F and 1H images.
Discussion
A novel 19F MRA protocol for the detection of well-circulated
intravascular PCE without the use of gadolinium was successfully
designed, implemented and tested in vivo, while a quantitative
analysis including a comparison with 1H images is provided. The
GRE protocol had a similar in vitro detection limit as previously
and theoretically predicted for a TSE sequence [9]. If an average
human body weight of 70 kg and blood volume of 5 L are
assumed, the detection limit of 400 mM used in this study is well
below the dose of (1.35 g/kg)/(499 g/mol)*70 kg/5 L= 38 mM
that has already been administered in humans [14], although such
19F MRA in humans would of course need a separate study on
dose dependence. The main factors that allowed the GRE
protocol to perform with similar sensitivity as TSE are most likely
related to a higher number of signal averages, the use of a sensitive
quadrature surface coil and the fact that TSE sequences with
increased echo train length may suffer from a penalty in SNR. The
measured in vitro 19F relaxation times were in agreement with the
literature [15,16] and are expected to be constant over the
concentration range of PCE that can be found in vivo. The short T2
in venous blood may be explained by the presence of
deoxyhemoglobin.
In vivo, the PCE resonance peak was more than one order of
magnitude higher than those from isoflurane resonances in the
spectra, indicating that the concentration of isoflurane was low
when compared to that of PCE. This is consistent with the
observation that there was no visible signal from fat or lungs in the
19F images. However, a PCE accumulation was observed in the
liver, most likely due to uptake in the Kuppfer cells for clearance
from the body [17].
The scanning time of ,5 min per slice may be acceptable for in
vivo human scanning and is consistent with the expected ,7 h
intravascular retention time of the PCE emulsion in the blood-pool
[17]. However, our results were obtained on an experimental
high-field animal system. In humans, the translation of this
technology to lower field strengths (3T) may be necessary, but will
inevitably lead to a penalty in SNR, although our injected dosage
of 12 ml/g61.78 g/ml = 0.021 g PFC/kg bodyweight is consider-
ably lower than the 1.35 g PFC/kg bodyweight that has already
been used in clinical trials [14]. In the current study we were
unfortunately not able to use such doses both due to technical
limitations in the production of stable emulsions with high PCE
content and due to animal ethics committee limitations on
administering higher volumes. It should also be noted that such
large volume injections are contraindicated in patients who have
coronary artery, renal, or pulmonary disease and in those who
have severe hepatic disease [18]. However, with advanced and
commercially available hardware (32-channel coil tunable to both
1H and 19F frequencies, parallel imaging, partial k-space sampling)
on human high-field systems, imaging of one slice in,10 s may be
feasible using contrast agent concentrations similar to our study.
Furthermore, direct 3D GRE imaging will result in a similar SNR
as 2D GRE imaging albeit with an increased volumetric coverage.
Using a volume rather than a surface coil, the technique presented
Figure 4. Distribution of crown ether in the vasculature of the
thorax in a mouse in vivo, 3h after injection. Shown here is a 19F
MRA coronal maximum intensity projection created from 6 adjacent
slices with a thickness of 2mm each. The image shows the lumen of
several cardiovascular structures including the right ventricle (RV), left
ventricle (LV), abdominal aorta and vena cava (AA+VC), and a renal
artery (RA), as well as the liver (L).
doi:10.1371/journal.pone.0042236.g004
Figure 3. Three series of 3 in vivo mouse images, with 1H
reference images in the left column, 19F images in the middle
and a color image fusion of the two in the right column. a–c)
axial slice through the heart, with a ECG-triggered to counter motion
blurring, which is not needed in b because of the averaging (RV = right
ventricle, LV = left ventricle, AA= abdominal aorta). d–f) Coronal slice
through the lungs (dark at the top), DA and the kidneys (at the bottom),
where the renal artery (RA) can be discerned. g–i) Axial slice at the level
of the liver. In h, the hepatic artery (HA) and several others can be
discerned while PCE is also temporarily stored in the surrounding liver
tissue, thus decreasing the conspicuity of the vessels. j–l) Coronal slice
through the abdominal aorta. Varying vessel contrast can be observed
in j, which is not present in k.
doi:10.1371/journal.pone.0042236.g003
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here may be extended for direct perfusion imaging as was recently
partially demonstrated for the kidneys [19], since the signal can be
quantified and the exact concentration determined with the
addition of an external reference phantom.
The SNR of the 19F images was considerably lower than that of
the 1H images (17 vs. 83), as expected and mainly caused by the
lower concentration of PCE relative to water in the lumen blood-
pool. The image quality is still limited, but longer scanning times,
higher concentrations of contrast media or advances in hardware
and software are likely to contribute to further improvement,
although it has to be considered that prolonged scanning times
may adversely affect image quality due to motion artifacts. The
large difference in SNR between the 1H and 19F images is also the
reason why the CNR is higher in the 1H images despite their lower
‘‘pure’’ contrast: the noise term appears to be more dominant than
the difference in signal. However, the vessel tracking in the 19F and
1H images resulted in significantly higher vessel sharpness in the
19F images, most likely since the ‘‘pure’’ contrast between the
vessel and the adjacent tissue is the dominant factor.
In conclusion, 19F magnetic resonance angiography of an
intravenously administered perfluorocarbon emulsion supports an
exclusive visualization of the vasculature in vivo due to the lack of
background signal and provides a promising alternative, flow-
independent angiographic MR technique. Since perfluoro-15-
crown-5-ether is inert and non-toxic, a translation to the human
setting seems feasible.
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